THE DEAL, AT A GLANCE
From the announcementOxford spin-out Alethio Therapeutics
01Who is involvedBacked by University of OxfordFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedOxford spin-out Alethio Therapeutics raised Series A, announced 2026-11-06From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersOxford spin-out Alethio Therapeutics is recorded as a Series A funding event in Unclassified, a category with 953 other funding rounds totaling $381758M in the trailing…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Oxford spin-out Alethio Therapeutics · Financing Record
Explore source-linked visual explanations for Oxford spin-out Alethio Therapeutics. Unsupported claims are withheld while source review continues.
Record 15438 · Recorded date: 2026-11-06
What it does
Founded as a University of Oxford spin-out by two globally recognised haematologist physician-scientists, Alethio builds on pioneering research that has advanced the understanding of these diseases.
Source: alethiotherapeutics.com ↗